logo
Share SHARE
FONT-SIZE Plus   Neg

Cytokinetics Inc. (CYTK) Is Down Sharply On Study Results

Cytokinetics Inc. (CYTK) and Amgen (AMGN) announced Tuesday that data from the ATOMIC-AHF Phase 2 study did not meet its primary endpoint of dyspnea response as measured by the 7-point Likert scale through 48 hours.

Cytokinetics gapped open sharply lower Tuesday and is now down 2.26 at $8.21 on above average volume. The stock has dropped to a month and a half low.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT